scout

Nisha Joseph, MD

Articles by Nisha Joseph, MD

5 panelists

Duration of Therapy and De-escalation: Navigating the Unknowns

BySundar Jagannath, MBBS,Ajay Nooka, MD, MPH, FACP,Mohan Krishnamachary, MD,Nisha Joseph, MD,Donna Catamero, MSN, ANP-BC, OCN, CBCN

Here, the panel turns to one of the most debated questions surrounding bispecific antibodies: how long should patients remain on therapy? Jagannath raises a scenario involving a patient who achieves MRD-negative complete remission after 1 and 2 years of therapy, prompting discussion about whether to continue, taper, or discontinue treatment.

CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways

BySagar Lonial, MD, FACP,Ajay K. Nooka, MD,Nisha Joseph, MD,Jonathan Kaufman, MD

Panelists discuss successful collaborations between academic centers and community practices in the context of (chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, key lessons learned in integrating CAR T therapy into the treatment landscape, and future plans for expanding CAR T therapy’s role in earlier lines of multiple myeloma treatment.

Care Coordination and Transition Strategies for CAR-T Therapy

BySagar Lonial, MD, FACP,Ajay K. Nooka, MD,Nisha Joseph, MD,Jonathan Kaufman, MD

Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.

CAR-T Therapy: Approach to Bridging

BySagar Lonial, MD, FACP,Ajay K. Nooka, MD,Nisha Joseph, MD,Jonathan Kaufman, MD

Panelists explain how CAR-T cell therapy works and describe the treatment process, discussing whether CAR -T is considered a complex procedure at their institution or if the logistics have been streamlined into clinical workflows, and they also detail their institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion, including whether patients are managed in-house or sent back to community centers.

Understanding the CAR-T Treatment Process

BySagar Lonial, MD, FACP,Ajay K. Nooka, MD,Nisha Joseph, MD,Jonathan Kaufman, MD

Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient evaluation and selection.

Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma

BySagar Lonial, MD, FACP,Ajay K. Nooka, MD,Nisha Joseph, MD,Jonathan Kaufman, MD

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.

Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

ByAshwin Kishtagari, MD,Vivek Govind Patel, MD,Nisha Joseph, MD,Martha Arellano, MD ,Colin Vale, MD

Experts provide extended follow-up on efficacy and safety outcomes with initial therapy combining ponatinib and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910

ByAshwin Kishtagari, MD,Vivek Govind Patel, MD,Nisha Joseph, MD,Martha Arellano, MD ,Colin Vale, MD

Experts present findings on blinatumomab consolidation therapy from the Phase 3 ECOG-ACRIN E1910 trial in adult patients with newly diagnosed B-lineage acute lymphoblastic leukemia who achieved measurable residual disease-negative remission.

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

ByAshwin Kishtagari, MD,Vivek Govind Patel, MD,Nisha Joseph, MD,Martha Arellano, MD ,Colin Vale, MD

Experts provide the first report of results from the Phase 3 PhALLCON trial comparing initial therapy with ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Latest Updated Articles